Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 102

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 102
---
 or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability
may differ in certain countries, particularly developing countries. Certain countries in Europe and developing countries, including China
and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries,
Kadimastem and its licensors may have limited remedies if patents are infringed or if it or its licensors are compelled to grant a license
to a third party, which could materially diminish the value of those patents. This could limit its potential revenue opportunities. Accordingly,
its efforts to enforce its intellectual property rights around the world may be inadequate to obtain a significant commercial advantage
from the intellectual property that it develops or licenses.

If Kadimastem is unable to maintain effective proprietary rights for its product candidates, it may not be able to compete effectively in its markets.

In addition to the protection
afforded by any patents currently owned and that may be granted, historically, it has relied on trade secret protection and confidentiality
agreements to protect proprietary know-how that is not patentable or that Kadimastem elects not to patent, processes that are not easily
known, knowable or easily ascertainable, and for which patent infringement is difficult to monitor and enforce and any other elements
of its product candidate discovery and development processes that involve proprietary know-how, information or technology that is not
covered by patents. However, trade secrets can be difficult to protect. Kadimastem seeks to protect its proprietary technology and processes,
in part, by entering into confidentiality agreements with its employees, consultants, scientific advisors, and contractors. It also seeks
to preserve the integrity and confidentiality of its data, trade secrets and intellectual property by maintaining physical security of
its premises and physical and electronic security of its information technology systems. Agreements or security measures may be breached,
and Kadimastem may not have adequate remedies for any breach. In addition, Kadimastem’s trade secrets and intellectual property
may otherwise become known or be independently discovered by competitors.

<div align='center'>69</div>

Kadimastem cannot provide
any assurances that its trade secrets and other confidential proprietary information will not be disclosed in violation of its confidentiality
agreements or that competitors will not otherwise gain access to its trade secrets or independently develop substantially equivalent information
and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of its trade secrets and intellectual property could
impair its competitive position and may have